2.60
+0.04(+1.56%)
Currency In USD
| Previous Close | 2.56 |
| Open | 2.55 |
| Day High | 2.66 |
| Day Low | 2.55 |
| 52-Week High | 5.54 |
| 52-Week Low | 2.38 |
| Volume | 716,523 |
| Average Volume | 720,311 |
| Market Cap | 155.69M |
| PE | 4 |
| EPS | 0.65 |
| Moving Average 50 Days | 3.08 |
| Moving Average 200 Days | 3.65 |
| Change | 0.04 |
If you invested $1000 in Eledon Pharmaceuticals, Inc. (ELDN) 10 years ago, it would be worth $1.44 as of August 24, 2025 at a share price of $2.6. Whereas If you bought $1000 worth of Eledon Pharmaceuticals, Inc. (ELDN) shares 5 years ago, it would be worth $329.11 as of August 24, 2025 at a share price of $2.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GlobeNewswire Inc.
Aug 06, 2025 8:01 PM GMT
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegopruba
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
GlobeNewswire Inc.
Jul 30, 2025 8:05 PM GMT
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinic
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
GlobeNewswire Inc.
Jul 17, 2025 8:01 PM GMT
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in